Cargando…

Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer

Treatment of triple-negative breast cancer is challenging. Standard adjuvant tretment is considered to be the cobination of anthracycline and taxanes although the role of anthracyclines administered preoperatively remains controversial. Actually, some studies recommended taxane-only regimens. We re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bacinschi, Xenia Elena, Zgura, Anca, Safta, Inga, Anghel, Rodica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685384/ https://www.ncbi.nlm.nih.gov/pubmed/33244272 http://dx.doi.org/10.2147/CMAR.S274104

Ejemplares similares

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
por: Ilie, Silvia Mihaela, et al.
Publicado: (2018)

Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
por: Bacinschi, Xenia Elena, et al.
Publicado: (2020)

Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy
por: Xenia Elena, Bacinschi, et al.
Publicado: (2021)

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
por: Bacinschi, Xenia, et al.
Publicado: (2022)

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy
por: Toma, Radu Valeriu, et al.
Publicado: (2023)

Quantitative Analysis of SPECT-CT Data in Metastatic Breast Cancer Patients—The Clinical Significance
por: Gherghe, Mirela, et al.
Publicado: (2022)

The Efficacy of Immunotherapy in Long-Term Survival in Non-Small Cell Lung Cancer (NSCLC) Associated with the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
por: Rahnea-Nita, Roxana-Andreea, et al.
Publicado: (2023)

An Overview of Cytomegalovirus Infection in Pregnancy
por: Plotogea, Mihaela, et al.
Publicado: (2022)

Entities, relations, events: representing biomolecular semantics
por: Pyysalo, Sampo
Publicado: (2010)

A Prospective Observational Study of 42 Patients with COVID-19 infection and a History of Hepatitis C Virus Infection and Thyroid Disease with Follow-Up Thyroid Function and Autoantibody Testing
por: Badiu, Dumitru Cristinel, et al.
Publicado: (2021)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
por: Absmaier, Magdalena, et al.
Publicado: (2018)

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy
por: Biesaga, Beata, et al.
Publicado: (2014)

A review of NTRK fusions in cancer
por: Manea, Cristina Alexandra, et al.
Publicado: (2022)

FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
por: Xu, Y. L., et al.
Publicado: (2017)

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012)

Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer
por: Deacu, Mariana, et al.
Publicado: (2021)

Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
por: Lee, Miseon, et al.
Publicado: (2019)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
por: Fernández-Cuesta, Lynnette, et al.
Publicado: (2012)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma
por: Gonzalez-Sistal, Angel, et al.
Publicado: (2016)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

Long-term oncological outcome in patients with cervical cancer after 3 trimodality treatment (radiotherapy, platinum-based chemotherapy, and robotic surgery)
por: Trifanescu, Oana Gabriela, et al.
Publicado: (2021)

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
por: West, Nathan R, et al.
Publicado: (2011)

Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates
por: Liebl, Magdalena C., et al.
Publicado: (2022)

Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma
por: Tamma, Roberto, et al.
Publicado: (2018)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group
por: Biesaga, Beata, et al.
Publicado: (2012)

The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update
por: Sascău, Radu, et al.
Publicado: (2021)

Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
por: Pandey, Sony, et al.
Publicado: (2018)

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
por: Wang, Jiachen, et al.
Publicado: (2021)

Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity
por: Wei, Hudie, et al.
Publicado: (2023)

Myocardial protection of propofol on apoptosis induced by anthracycline by PI3K/AKT/Bcl-2 pathway in rats
por: Zhang, Xiaobei, et al.
Publicado: (2022)

Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
Publicado: (2022)

The Analysis of bcl-2 in Association with p53 and Ki-67 in Triple Negative Breast Cancer and Other Molecular Subtypes in Ghana
por: Ameh-Mensah, Charity, et al.
Publicado: (2021)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ilmb2jppb7si3vlfnftb0kbfcb